Cellerant Appoints Rodney Young as Chief Financial Officer SAN CARLOS, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic (blood forming) stem cell-based cellular and antibody...

Cellerant Announces Dosing of First Patient in Randomized Phase 2 Clinical Trial of CLT-008 in Acute Myeloid Leukemia Patients SAN CARLOS, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic (blood forming) stem cell-based cellular and antibody...

Cellerant to Present Phase 1 Clinical Data on Evaluation of CLT-008 in Patients With Acute Myeloid Leukemia at the 2014 American Society of Hematology Annual Meeting SAN CARLOS, Calif., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., announced that data from the Phase 1 clinical trial for CLT-008, a first-in-class, allogeneic, cell-based therapy for...

Cellerant Awarded $47.5 Million Under Existing U.S. Government Contract to Support Development of CLT-008 Total Contract With Biomedical Advanced Research and Development Authority Valued at $163.8MM Additional Funding to Support Planned Phase 2 Trial With CLT-008 in AML SAN CARLOS, Calif., Sept....